Skip to main content

Table 2 Comparison of the changes of ERO, JSN, mTSS scores, and clinical scores at 12 months

From: Effect of denosumab switched from bisphosphonates in preventing joint destruction in postmenopausal rheumatoid arthritis patients with anti-cyclic citrullinated peptide antibodies

Variable

Bisphosphonate group (n = 50)

Denosumab group (n = 56)

p value

Modified sharp erosion score

1.16 (1.47)

0.72 (1.58)

0.015*

Modified sharp JSN score

0.24 (0.55)

0.27 (0.84)

0.92

Modified total sharp score

1.56 (2.15)

1.12(2.31)

0.01**

DAS28-CRP

0.1 (0.74)

0.04 (0.53)

0.9

VAS

0.96 (18.1)

0.82 (15.7)

0.82

mHAQ

0.014 (0.23)

0.021 (0.31)

0.72

  1. Results are expressed as the mean and standard deviation
  2. DAS disease activity score, CRP C-reactive protein, VAS visual analogue scale, HAQ Health Assessment Questionnaire
  3. *p < 0.05; **p < 0.01 by Mann–Whitney U test